Santarus Completes Patient Enrollment in CONTRIBUTE Study with UCERIS

Santarus, Inc. SNTS today announced the completion of enrollment in the CONTRIBUTE clinical study designed to evaluate the incremental benefit of adding UCERIS (budesonide) extended release 9 mg tablets to oral aminosalicylate (5-ASA) therapy for the induction of clinical remission in adult patients with active, mild to moderate ulcerative colitis. UCERIS is currently approved in the U.S. for the induction of remission in patients with active, mild to moderate ulcerative colitis. A total of 509 patients were enrolled in the CONTRIBUTE study, a multicenter, randomized, double-blind, placebo controlled clinical trial. The primary endpoint of the study is clinical remission, defined as a score of 0 for both rectal See full press release